沙库巴曲缬沙坦在心血管疾病中的研究进展

doi:10.3969/j.issn.1004-583X.2021.11.016

摘要/Abstract

摘要：

心血管疾病已成为医疗系统的重大负担之一,尽管治疗手段众多,但发病率及病死率仍较高,亟需研发新型药物。沙库巴曲缬沙坦(LCZ696)作为首个血管紧张素受体脑啡肽酶抑制剂(ARNI),通过抑制脑啡肽酶活性和拮抗血管紧张素Ⅱ 1型受体发挥双重作用。本文就LCZ696在左心室射血分数(LVEF)降低的心力衰竭、急性失代偿性心力衰竭、LVEF保留的心力衰竭、急性心肌梗死、高血压、心律失常、心肌病等心血管疾病中的研究进展进行综述。

关键词: 心血管疾病, 沙库巴曲缬沙坦, 临床应用, 作用机制

中图分类号:

简郭进, 张斌. 沙库巴曲缬沙坦在心血管疾病中的研究进展[J]. 临床荟萃, 2021, 36(11): 1041-1045.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.11.016

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I11/1041

参考文献 41

[1]	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35(9):833-854.
[2]	Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014, 63(12):1123-1133. doi: S0735-1097(14)00291-5 pmid: 24491689
[3]	Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications[J]. Circulation, 1990, 81(4):1161-1172. doi: 10.1161/01.cir.81.4.1161 pmid: 2138525
[4]	李崇耀, 张曼, 赵鸿斌, 等. 沙库巴曲缬沙坦联合芪苈强心胶囊治疗慢性心力衰竭患者的临床疗效观察[J]. 疑难病杂志, 2020, 19(7):667-671.
[5]	刘岳, 汪芳. 沙库巴曲缬沙坦的药代动力学和药效学特点[J]. 中国循环杂志, 2018, 33(2):198-200.
[6]	Rodgers JE. Sacubitril/valsartan: The newest addition to the toolbox foe guideline-directed medical therapy of heart failure[J]. Am J Med, 2017, 130(6):635-639. doi: S0002-9343(17)30216-4 pmid: 28285069
[7]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[8]	Yandrapalli S, Khan MH, Rochlani Y, et al. Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy[J]. Ther Adv Cardiovasc Dis, 2018, 12(8):217-231. doi: 10.1177/1753944718784536 pmid: 29921166
[9]	Kang DH, Park SJ, Shin SH, et al. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation[J]. Circulation, 2019, 139(11):1354-1365. doi: 10.1161/CIRCULATIONAHA.118.037077 URL
[10]	Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction[J]. JAMA, 2019, 322(11):1085-1095. doi: 10.1001/jama.2019.12821 URL
[11]	Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study[J]. Eur J Heart Fail, 2019, 21(8):998-1007. doi: 10.1002/ejhf.1498 pmid: 31134724
[12]	Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure[J]. N Engl J Med, 2019, 380(6):539-548. doi: 10.1056/NEJMoa1812851 URL
[13]	Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851):1387-1395. doi: 10.1016/S0140-6736(12)61227-6 pmid: 22932717
[14]	Solomon SD, McMurray JJV, Anand IS, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction[J]. N Engl J Med, 2019, 381(17):1609-1620. doi: 10.1056/NEJMoa1908655 URL
[15]	Solomon SD, Vaduganathan M, L Claggett B, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure[J]. Circulation, 2020, 141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586 pmid: 31736342
[16]	McMurray JJV, Jackson AM, Lam CSP, et al. Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: Insights from PARAGON-HF[J]. Circulation, 2020, 141(5):338-351. doi: 10.1161/CIRCULATIONAHA.119.044491 pmid: 31736337
[17]	Wachter R, Shah SJ, Cowie MR, et al. Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: Design and rationale of the PARALLAX trial[J]. ESC Heart Fail, 2020, 7(3):856-864. doi: 10.1002/ehf2.12694 pmid: 32297449
[18]	Selvaraj S, Claggett BL, Packer M, et al. Effects of Sacubitril/valsartan on serum lipids in heart failure with preserved ejection fraction[J]. J Am Heart Assoc, 2021, 16:e022069.
[19]	Mc Causland FR, Lefkowitz MP, Claggett B, et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction[J]. Circulation, 2020, 142(13):1236-1245. doi: 10.1161/CIRCULATIONAHA.120.047643 pmid: 32845715
[20]	Qureshi WT, Zhang ZM, Chang PP, et al. Silent myocardial infarction and long-term risk of heart failure: The ARIC study[J]. J Am Coll Cardiol, 2018, 71(1):1-8. doi: S0735-1097(17)41438-0 pmid: 29301615
[21]	Torrado J, Cain CK, Mauro AG, et al. Sacubitril/Valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits[J]. J Am Coll Cardiol, 2018, 72(19):2342-2356. doi: S0735-1097(18)38437-7 pmid: 30384891
[22]	Ishii M, Kaikita K, Sato K, et al. Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction[J]. JACC Basic Transl Sci, 2017, 2(6):655-668.
[23]	Zhang Y, Wu Y, Zhang K, et al. Benefits of early administration of sacubitril/valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention[J]. Coron Artery Dis, 2021, 32(5):427-431. doi: 10.1097/MCA.0000000000000955 URL
[24]	Rezq A, Saad M, El Nozahi M. Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction[J]. Am J Cardiol, 2021, 143:7-13. doi: 10.1016/j.amjcard.2020.12.037 URL
[25]	Jering KS, Claggett B, Pfeffer MA, et al. Prospective ARNI versus ACE inhibitor trial to determIne superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): Design and baseline characteristics[J]. Eur J Heart Fail, 2021, 23(6):1040-1048. doi: 10.1002/ejhf.v23.6 URL
[26]	Williams B, Cockcroft JR, Kario K, et al. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study[J]. Hypertension, 2017, 69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556 pmid: 28093466
[27]	Williams B, Lacy PS, Baschiera F, et al. Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The ambulatory central aortic pressure (AmCAP) study[J]. Hypertension, 2013, 61(6):1168-1176. doi: 10.1161/HYPERTENSIONAHA.111.00763 pmid: 23630950
[28]	Zheng L, Xia B, Zhang X, et al. A meta-analysis on the effect and safety of LCZ696 in the treatment of hypertension[J]. Cardiol Res Pract, 2021, 2021(1):1-10.
[29]	Wang TD, Tan RS, Lee HY, et al. Effects of sacubitril/valsartan (LCZ696) on natriuresis, diuresis, blood pressures, and NT-proBNP in salt-sensitive hypertension[J]. Hypertension, 2017, 69(1):32-41. doi: 10.1161/HYPERTENSIONAHA.116.08484 URL
[30]	Kario K, Tamaki Y, Okino N, et al. LCZ696, a first-in-class angiotensin receptor-neprilysin inhibitor: The first clinical experience in patients with severe hypertension[J]. J Clin Hypertens (Greenwich), 2016, 18(4):308-314. doi: 10.1111/jch.12667 URL
[31]	Ito S, Satoh M, Tamaki Y, et al. Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction[J]. Hypertens Res, 2015, 38(4):269-275. doi: 10.1038/hr.2015.1 URL
[32]	Martens P, Nuyens D, Rivero-Ayerza M, et al. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction[J]. Clin Res Cardiol, 2019, 108(10):1074-1082. doi: 10.1007/s00392-019-01440-y pmid: 30788621
[33]	Chang PC, Wo HT, Lee HL, et al. Sacubitril/valsartan therapy ameliorates ventricular tachyarrhythmia inducibility in a rabbit myocardial infarction model-science direct[J]. J Card Fail, 2020, 26(6):527-537. doi: 10.1016/j.cardfail.2020.03.007 URL
[34]	李倩, 李昕, 李路安, 等. 沙库巴曲缬沙坦通过逆转高血压大鼠心房结构重塑降低房颤易感性[J]. 中国药理学通报, 2021, 37(5):631-637.
[35]	王涛, 易登良, 范忠才. 沙库巴曲缬沙坦对糖尿病心肌病大鼠的保护作用及其机制[J]. 西安交通大学学报(医学版), 2021, 42(1):42-47.
[36]	Kim HM, Kim KH, Park JS, et al. Beneficial effect of left ventricular remodeling after early change of sacubitril/valsartan in patients with nonischemic dilated cardiomyopathy[J]. Medicina (Kaunas), 2021, 57(5):416.
[37]	Tafelmeier M, Baessler A, Wagner S, et al. Design of the SILICOFCM study: effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy[J]. Clin Cardiol, 2020, 43(5):430-440. doi: 10.1002/clc.23346 pmid: 32125709
[38]	Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2016, 37(27):2129-2200. doi: 10.1093/eurheartj/ehw128 pmid: 27206819
[39]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: areport of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017, 23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014 URL
[40]	王华, 梁延春. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10):760-789.
[41]	Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: Pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology[J]. Eur J Heart Fail, 2019, 21(10):1169-1186. doi: 10.1002/ejhf.1531 pmid: 31129923

沙库巴曲缬沙坦在心血管疾病中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 15

编辑推荐

Metrics

本文评价

[1]	顾天舒, 梁雪, 蔡嘉庚, 李广平. m6A RNA甲基化修饰在心血管疾病中的进展[J]. 临床荟萃, 2023, 38(8): 743-748.
[2]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[3]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[4]	张怡, 崔晓冉, 杨晓红. 单核细胞/高密度脂蛋白胆固醇比值在心血管疾病中研究进展[J]. 临床荟萃, 2022, 37(6): 551-555.
[5]	李百远, 李元军. 他汀类药物辅助抗结核作用机制及临床价值[J]. 临床荟萃, 2022, 37(2): 166-169.
[6]	张磊, 娄海东, 智昱, 亓树莹. PCSK9抑制剂对动脉粥样硬化性心血管疾病有效性及安全性的meta分析[J]. 临床荟萃, 2022, 37(12): 1074-1080.
[7]	杨瑞, 刘宇宏. 类风湿关节炎患者血脂水平与心血管疾病风险相关研究进展[J]. 临床荟萃, 2022, 37(1): 92-96.
[8]	叶蒙蒙, 李旎, 徐国栋, 邵国丰. miR-361在心血管疾病的研究进展[J]. 临床荟萃, 2021, 36(9): 843-849.
[9]	卢昊阳, 卢家忠, 韩明锋, 吕新才, 张标, 戎成振, 贾蕾蕾, 潘强强, 马蕾蕾, 赵韧. 新型冠状病毒肺炎合并心血管疾病的临床治疗观察[J]. 临床荟萃, 2021, 36(3): 203-207.
[10]	梁欢1，刘建凤2. 盘点钠-葡萄糖协同转运蛋白2抑制剂临床研究新进展[J]. 临床荟萃, 2020, 35(9): 861-864.
[11]	王文君，何学志，高峰，庄熙晶. 选择性血管加压素V2受体拮抗剂在心脏大血管外科围手术期的临床应用进展[J]. 临床荟萃, 2020, 35(9): 853-856.
[12]	年士艳a，冯磊b. 云南省元江县傣族、哈尼族和彝族心血管病相关生化指标的差异性研究[J]. 临床荟萃, 2020, 35(8): 689-692.
[13]	贺玉琴1，刘永铭2，闫芳芳1. LCZ696治疗心力衰竭有效性与安全性meta分析[J]. 临床荟萃, 2020, 35(7): 581-588.
[14]	郝珍1，李巍2a，于洪伟2b，江珊2b. 沙库巴曲缬沙坦钠对左心室射血分数保留心力衰竭患者的近期疗效[J]. 临床荟萃, 2020, 35(6): 503-507.
[15]	刘晓腾a, 张英a, 金凤表b, 刘慧卿a, 高宇b, 李青联a, 侯瑞田a. 成纤维细胞生长因子21在糖脂代谢及心血管疾病中的研究进展[J]. 临床荟萃, 2020, 35(5): 472-475.